94 related articles for article (PubMed ID: 33619913)
1. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725
[TBL] [Abstract][Full Text] [Related]
4. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
[TBL] [Abstract][Full Text] [Related]
5. Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
Yan N; Zhang H; Shen S; Guo S; Li X
BMC Cancer; 2024 Feb; 24(1):178. PubMed ID: 38317126
[TBL] [Abstract][Full Text] [Related]
6. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
Scobie MR; Zhou KI; Ahmed S; Kelley MJ
JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
[TBL] [Abstract][Full Text] [Related]
7.
Brown LC; Tucker MD; Sedhom R; Schwartz EB; Zhu J; Kao C; Labriola MK; Gupta RT; Marin D; Wu Y; Gupta S; Zhang T; Harrison MR; George DJ; Alva A; Antonarakis ES; Armstrong AJ
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653800
[TBL] [Abstract][Full Text] [Related]
8. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract][Full Text] [Related]
9. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
10. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.
Niwa K; Kawakita D; Nagao T; Takahashi H; Saotome T; Okazaki M; Yamazaki K; Okamoto I; Hirai H; Saigusa N; Fushimi C; Masubuchi T; Miura K; Okazaki SI; Matsui H; Okada T; Iwaki S; Matsuki T; Hanyu K; Tsukahara K; Oridate N; Tada Y
Sci Rep; 2020 Oct; 10(1):16988. PubMed ID: 33046752
[TBL] [Abstract][Full Text] [Related]
11. A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.
Lu M; Wu KH; Trudeau S; Jiang M; Zhao J; Fan E
Sci Rep; 2020 Nov; 10(1):20575. PubMed ID: 33239757
[TBL] [Abstract][Full Text] [Related]
12. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings.
Kapoor A; Noronha V; Patil VM; Menon N; Joshi A; Abraham G; Prabhash K
Medicine (Baltimore); 2021 Apr; 100(13):e25115. PubMed ID: 33787593
[TBL] [Abstract][Full Text] [Related]
15. Survival in metastatic microsatellite-stable colorectal cancer correlated with tumor mutation burden and mutations identified by next-generation sequencing.
Taflin N; Sandow L; Thawani R; Ye S; Kardosh A; Corless CL; Chen EY
J Gastrointest Oncol; 2024 Apr; 15(2):681-688. PubMed ID: 38756628
[TBL] [Abstract][Full Text] [Related]
16. Association of ERCC family mutations with prognosis and immune checkpoint inhibitors response in multiple cancers.
Chen C; Liu H; Li Y; Liu J
Sci Rep; 2023 Aug; 13(1):13925. PubMed ID: 37626083
[TBL] [Abstract][Full Text] [Related]
17. GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.
Li GX; Chang RZ; Liu TT; Jin GN; Lu K; Yong TY; Li Z; Liu JH; Zhang B; Zhang WG; Ding ZY
Cancer Gene Ther; 2024 Apr; 31(4):586-598. PubMed ID: 38267623
[TBL] [Abstract][Full Text] [Related]
18. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors.
Maleki Vareki S
J Immunother Cancer; 2018 Dec; 6(1):157. PubMed ID: 30587233
[TBL] [Abstract][Full Text] [Related]
19. Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
Pabla S; Seager RJ; Van Roey E; Gao S; Hoefer C; Nesline MK; DePietro P; Burgher B; Andreas J; Giamo V; Wang Y; Lenzo FL; Schoenborn M; Zhang S; Klein R; Glenn ST; Conroy JM
Biomark Res; 2021 Jul; 9(1):56. PubMed ID: 34233760
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Chen P; Long J; Zhang J; Xie F; Wu W; Tian Z; Zhang S; Yu K
Inflamm Res; 2024 Feb; 73(2):263-276. PubMed ID: 38200372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
